AIX 9.01 ▲0.33% ALU 0.88 ▼-2.22% DN1 99.70 ▼-0.09% EMUCA 0.89 KIT 1.90 ▲0.00% KKC 2.11 ▲0.00% LF1 1.92 ▲0.79% MBG 0.14 ▲0.00% MRE 1.88 ▼-0.53% PCI 1.09 ▼-0.91% PCX 1.99 ▼-0.75% RF1 3.52 ▼-0.28% SET 2.14 ▼-0.47% TET 0.22 ▼-2.22% WMX 1.69 ▼-1.17% BST 0.30 ▲3.45% CTS 0.56 ▲1.82% EFR 0.00 ▲0.00% AIX 9.01 ▲0.33% ALU 0.88 ▼-2.22% DN1 99.70 ▼-0.09% EMUCA 0.89 KIT 1.90 ▲0.00% KKC 2.11 ▲0.00% LF1 1.92 ▲0.79% MBG 0.14 ▲0.00% MRE 1.88 ▼-0.53% PCI 1.09 ▼-0.91% PCX 1.99 ▼-0.75% RF1 3.52 ▼-0.28% SET 2.14 ▼-0.47% TET 0.22 ▼-2.22% WMX 1.69 ▼-1.17% BST 0.30 ▲3.45% CTS 0.56 ▲1.82% EFR 0.00 ▲0.00%

NAN Nanosonics Limited

Healthcare · Medical Instruments & Supplies · website · 470 employees
$3.18
52wk 2.94 – 4.77
Overall
Value
Growth
Health
Quality
Momentum
Dividend
Price
About Nanosonics Limited

Nanosonics Limited operates as an infection prevention company in Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific. The company manufactures and distributes trophon ultrasound probe disinfector, and its related consumables and accessories; and research, develops, and commercialize of infection control and decontamination products and related technologies. It also provides trophon2 a device with an enhanced design and new functionality, including AcuTrace TM for audit-ready digital record-keeping and capabilities to connect trophon 2 with hospital IT systems; AuditPro nanosonics, an infection control workflow compliance management; Trophon EPR, a patented sonicated mist technology that provides high level disinfection of both endocavitary and surface ultrasound probes; and CORIS, an instrument reprocessing product platform. Nanosonics Limited was incorporated in 2000 and is headquartered in Macquarie Park, Australia.

Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$950.54M
P/E (trailing)
45.43
P/E (forward)
43.31
EPS (trailing)
0.07
Dividend yield
Payout ratio
0.0%
Beta
1.20
EV / EBITDA
32.41
Price / Book
4.39
ROE
10.1%
Operating margin
8.9%
Net margin
9.9%
Total cash
$159.83M
Total debt
$6.67M
Current ratio
6.40
Debt / Equity
0.03
Free cash flow
$9.13M
Avg volume
602,954
Latest annual results (FY ending 30 Jun 2025)
  • Revenue$198.93M
  • Gross profit$155.66M
  • Operating income$8.93M
  • Net income$20.68M
  • Diluted EPS0.07
  • Free cash flow$35.26M
  • Net debt-$153.61M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $59.53B 14.0
RMD $43.89B 20.4
SIG $34.28B 59.4
FPH $20.25B 52.2
PME $17.21B 73.5
SHL $10.79B 19.7
RHC $10.13B 34.8
COH $7.90B 22.9